Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Published:2013-10 Issue:11 Volume:14 Page:1055-1066
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Miguel Jesus San,Weisel Katja,Moreau Philippe,Lacy Martha,Song Kevin,Delforge Michel,Karlin Lionel,Goldschmidt Hartmut,Banos Anne,Oriol Albert,Alegre Adrian,Chen Christine,Cavo Michele,Garderet Laurent,Ivanova Valentina,Martinez-Lopez Joaquin,Belch Andrew,Palumbo Antonio,Schey Stephen,Sonneveld Pieter,Yu Xin,Sternas Lars,Jacques Christian,Zaki Mohamed,Dimopoulos Meletios

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib therapy: a multicentre International Myeloma Working Group study;Kumar;Leukemia,2012

2. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma;Quach;Leukemia,2010

3. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus lowdose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI);Matous;J Clin Oncol,2013

4. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma;Schey;J Clin Oncol,2004

5. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation;Streetly;Br J Haematol,2008

Cited by 707 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma;Current Medical Research and Opinion;2024-09-03

2. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial;Nature Communications;2024-08-27

4. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study;Blood;2024-08-08

5. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08